Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 3/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19370107 | 0.95 | MAPT (0.55) | MAPTRAB9ASMN1; SMN2HDAC7MAOB | |
| SCHEMBL31006340 | 0.95 | MAPT (0.55) | MAPTRAB9ASMN1; SMN2HDAC7MAOB | |
| SCHEMBL12459480 | 0.90 | L3MBTL1 (0.58) | MAPTRAB9ASMN1; SMN2MAOBL3MBTL1 | |
| SCHEMBL12452818 | 0.90 | MAPT (0.50) | MAPTRAB9ASMN1; SMN2HDAC7MAOB | |
| SCHEMBL25040676 | 0.84 | L3MBTL1 (0.53) | MAPTRAB9ASMN1; SMN2MAOBL3MBTL1 | |
| SCHEMBL30274345 | 0.84 | L3MBTL1 (0.53) | MAPTRAB9ASMN1; SMN2MAOBL3MBTL1 | |
| SCHEMBL10343975 | 0.83 | MAPT (0.61) | MAPTRAB9ASMN1; SMN2HDAC7L3MBTL1 | |
| SCHEMBL25144719 | 0.82 | MAPT (0.46) | MAPTRAB9ASMN1; SMN2HDAC7L3MBTL1 | |
| SCHEMBL10719302 | 0.81 | RAB9A (0.67) | MAPTRAB9ASMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL18522763 | 0.81 | SMN1; SMN2 (0.58) | MAPTRAB9ASMN1; SMN2HDAC7L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169660-A1 | CYCLIC AMINO-PYRAZINECARBOXAMIDE COMPOUNDS AND USES THEREOF | SILVERBACK THERAPEUTICS INC (US) | 2022-06-02 | — | — | US | disclosed |
| US-20110160196-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2011-06-30 | — | — | US | disclosed |
| US-20110160196-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2011-06-30 | — | — | US | disclosed |
| US-20080293704-A1 | FACTOR Xa INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080293704-A1 | FACTOR Xa INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293704-A1 | FACTOR Xa INHIBITORS | TFPI, F12, F11 | MAPT 4577/4885RAB9A 1789/4885SMN1; SMN2 3156/4885 |
| US-20110160196-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | MAPT 4577/4885RAB9A 1789/4885SMN1; SMN2 3156/4885 |
| US-20220169660-A1 | CYCLIC AMINO-PYRAZINECARBOXAMIDE COMPOUNDS AND USES THEREOF | TGFBR2, ACVR2A, SMAD2 | MAPT 3941/4885RAB9A 3009/4885SMN1; SMN2 3980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.